$196.7 M

ACER Mkt cap, 22-May-2019
Acer Therapeutics Net income (Q1, 2019)-8 M
Acer Therapeutics EBIT (Q1, 2019)-8.2 M
Acer Therapeutics Cash, 31-Mar-201931.8 M

Acer Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.3m1.3m2.6m

Revenue growth, %

0%101%

R&D expense

9.2m12.1m10.0m6.5m8.7m12.5m

General and administrative expense

3.7m3.8m4.3m3.1m5.2m9.3m

Operating expense total

12.9m16.0m14.3m9.6m13.9m21.7m

Depreciation and amortization

238.1k

EBIT

(11.9m)(15.1m)(12.1m)(8.0m)(13.9m)(21.7m)

EBIT margin, %

(941%)(1185%)(473%)

Interest income

15.0k15.5k5.9k874.014.8k412.6k

Net Income

(16.7m)(15.1m)(12.0m)(8.0m)(14.2m)(21.3m)

Acer Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

23.6m9.9m12.6m3.4m15.6m41.7m

Accounts Receivable

Inventories

Current Assets

24.8m10.7m13.6m3.8m16.5m42.7m

PP&E

63.0k130.9k

Goodwill

7.6m7.6m

Total Assets

26.2m11.8m14.4m3.9m24.4m50.7m

Accounts Payable

696.2k702.5k739.9k378.0k95.9k1.0m

Short-term debt

Current Liabilities

3.3m3.1m4.8m1.2m

Long-term debt

Total Debt

Total Liabilities

5.7m4.8m1.2m2.0m5.6m

Additional Paid-in Capital

146.6m148.5m162.9m164.0m47.8m91.9m

Retained Earnings

(141.3m)(153.3m)(161.3m)(25.6m)(46.8m)

Total Equity

20.6m7.4m9.6m2.7m22.3m45.1m

Financial Leverage

1.3 x1.6 x1.5 x1.4 x1.1 x1.1 x

Acer Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(16.7m)(15.1m)(12.0m)(8.0m)(14.2m)(21.3m)

Depreciation and Amortization

335.6k387.8k351.4k238.1k4.0k27.7k

Accounts Receivable

Inventories

Accounts Payable

6.3k37.4k(361.9k)(287.5k)938.0k

Cash From Operating Activities

(6.1m)(14.2m)(10.5m)(9.2m)(14.1m)(16.6m)

Purchases of PP&E

(62.8k)(95.6k)

Cash From Investing Activities

740.8k(190.9k)(92.3k)(1.2k)967.3k(95.6k)

Cash From Financing Activities

28.4m648.2k13.3m65.4k26.9m42.7m

Interest Paid

19.6k2.0k2.3k3.3k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q1, 2019

Net Income

(12.9m)(3.7m)(7.8m)(11.7m)(3.4m)(6.8m)(9.6m)(2.2m)(4.3m)(6.3m)(926.3k)(1.6m)(10.0m)(8.8m)(8.0m)

Depreciation and Amortization

258.1k95.6k194.2k291.6k97.0k191.0k280.0k72.6k138.2k190.3k2.7k11.0k9.5k

Accounts Payable

315.7k(186.0k)(162.0k)278.6k(79.9k)(371.1k)156.0k765.2k(972.7k)

Cash From Operating Activities

(2.5m)(3.9m)(7.3m)(10.5m)(222.2k)(3.7m)(6.8m)(2.5m)(4.6m)(6.9m)(1.0m)(2.0m)(9.9m)(7.2m)(9.8m)

Purchases of PP&E

(2.5k)(15.1k)(88.9k)

Cash From Investing Activities

785.8k(75.9k)(127.2k)(149.2k)(6.4k)(11.8k)(69.9k)(485.0)(1.2k)(1.2k)1.0m(15.1k)(88.9k)

Cash From Financing Activities

21.3m648.2k(104.9k)12.1m12.6m(82.7k)(161.1k)106.9k(38.7k)

Interest Paid

19.6k958.0747.01.0k50.01.4k2.2k2.4k1.2k1.8k

Income Taxes Paid

Acer Therapeutics Ratios

USDY, 2019

Financial Leverage

1.1 x